Healthcare Review: EDAP SA, Novartis, Herbalife, Abiomed, Alkermes plc Print E-mail
By Staff and Wire Reports   
Thursday, 31 July 2014 13:55
U.S. stocks slumped Thursday as investors reacted to disappointing corporate earnings reports and assessed the implications of the approaching end to economic stimulus from the Federal Reserve. That stimulus has underpinned gains in the stock market for years. Argentina's stock market plunged after the South American nation defaulted on its debt for the second time in 13 years.

Shares of EDAP SA ($EDAP) crater on a 6x surge in volume after the FDA's Gastroenterology and Urology Devices Ad Comm panel voted against recommending approval of the company's Ablatherm Integrated Imaging device for the treatment of prostate cancer.

In a just-published article detailing clinical trial results for Novartis' ($NVS -1.2%) antimalarial drug candidate, KAE609 (cipargamin), the parasite was cleared in adult patients in a median time of only 12 hours, including patients with resistant infections.

Herbalife ($HLF) has earmarked a newly-constructed facility in Jiangning High-tech Industry Park, Nanjing as its newest manufacturing site in China. The company will invest up to $400M to develop the facility in time to commence manufacturing by the end of 2015. It will ultimately produce up to 65% of the firm's product requirements in China.

Abiomed ($ABMD) fiscal Q1 results: Total Revenues: $48.8M (+14.3%); Operating Expenses: $50.3M (+14.3%); Operating Loss: ($1.5M) (-15.4%); Net Loss: ($1.7M) (+0.8%); Loss Per Share: ($0.04) (unch); Quick Assets: $87.1M (+14.1%).

Alkermes plc ($ALKS) Q2 results: $153.4M (+10.7%); Operating Expenses: $176.2M (+40.8%); Operating Loss: ($22.8M) (-268.9%); Net Income: $3.7M (-49.3%); Quick Assets: $713.9M (+58.6%). Total revenues: $580M - 610M (unch); COGS: $165M - 175M (unch); R&D: $260M - 280M from $225M - 245M; SG&A: $190M - 200M (unch); GAAP net loss: ($90M - 110M) from ($70M - 90M); GAAP EPS loss: ($0.62 - 0.76) from ($0.48 - 0.61); non-GAAP net income: $30M - 50M from $65M - 85M; non-GAAP EPS: $0.19 - 0.32 from $0.41 - 0.54; FCF: up to $20M from $30M - 50M.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter